Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1636
This examiner grants 67% of resolved cases
Qiwen NMN Su-Tobon is an examiner in Tech Center 1600 and Art Unit 1600. Her profile shows 6 resolved cases. Her allowance rate of 66.7 percent is relatively high, suggesting a favorable environment for applicants. However, with a small caseload, practitioners should be aware that her long-term statistical trends may still be developing. This 66.7 percent rate indicates that she is open to granting patents when the requirements are met.
The interview lift for Su-Tobon is also 66.7 percent, which is exceptionally high. This suggests that direct communication is a vital and highly effective strategy in her docket. An interview can dramatically increase the probability of an allowance, likely by facilitating a more productive exchange of ideas. Practitioners should consider an interview to be an essential step in their prosecution strategy to leverage this metric.
The median days to allowance for Su-Tobon is 1212. This timeline represents a pendency of an extended period. The combination of the allowance rate and the 1212-day median pendency suggests a relatively standard timeframe for patent prosecution. While the sample size is small, the initial data suggests that active engagement through interviews can lead to a successful outcome within a typical duration.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16972740 | AAV CARDIAC GENE THERAPY FOR CARDIOMYOPATHY | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17800417 | COMPOSITIONS AND METHODS FOR IDENTIFYING HOST CELL TARGET PROTEINS FOR TREATING RNA VIRUS INFECTIONS | Non-Final OA | The Regents of the University of California |
| 18312196 | ANASTASIS BIOSENSOR CASPASE TRACKER | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 16226714 | DNA METHYLATION MARKERS FOR METASTATIC PROSTATE CANCER | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18009534 | RIBOSWITCH MODULES AND METHODS FOR CONTROLLING EUKARYOTIC PROTEIN TRANSLATION | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18032868 | REPROGRAMMABLE ISCB NUCLEASES AND USES THEREOF | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 17849132 | METHODS AND COMPOSITIONS FOR INHIBITING CORONAVIRAL REPLICATION | Final Rejection | California Institute of Technology |
| 17928028 | MODULAR PLATFORM FOR PROGRAMMABLE SPATIOTEMPORAL BIOMOLECULE CLUSTERING WITH APPLICATIONS INCLUDING ENHANCED METABOLIC YIELD | Non-Final OA | The Trustees of Princeton University |
| 18287682 | PRODUCTS AND METHODS FOR INDUCING EXON 2 SKIPPING OF THE DMD GENE IN TREATING MUSCULAR DYSTROPHY | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18330563 | SUMO Targeting Morpholinos as both Enhancers of Anti-Cancer Effects of Chemotherapeutic Treatments and Preventative Agents Against the Establishment of Chemoresistance | Final Rejection | Board of Regents, The University of Texas System |
| 18262792 | PREVENTIVE OR THERAPEUTIC AGENT FOR BENIGN ADULT FAMILIAL MYOCLONIC EPILEPSY | Final Rejection | RIKEN |
| 18546378 | SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY | Non-Final OA | North Carolina State University |
| 18551668 | ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 18050511 | LACTIC ACID BACTERIA HAVING IMPROVED SUGAR METABOLISM | Non-Final OA | DUPONT NUTRITION BIOSCIENCES APS |
| 18262086 | CAS12I2 FUSION MOLECULES AND USES THEREOF | Non-Final OA | Arbor Biotechnologies, Inc. |
| 18453993 | METHOD AND COMPOSITION FOR A TARGETED GENE KNOCKOUT | Non-Final OA | Eberhard Karls Universität Tübingen Medizinische Fakultät |
| 18564885 | CYTOSOLIC DELIVERY OF GENOME EDITING TOOLS | Non-Final OA | SAPREME TECHNOLOGIES B.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy